## REMARKS

## Allowance of Claims 25-26

The Examiner's allowance of claims 25 and 26 of the present application, as indicated in the January 7, 2009 Office Action, is hereby acknowledged by the Applicants with gratitude.

## Response to §112 Enablement Rejection

In the January 7, 2009 Office Action, the Examiner reiterated the previously raised rejections against claims 1-4, 13, and 17-19 under 35 U.S.C. §112, first paragraph for lack of enablement.

Applicants respectfully disagree with the Examiner, for the same reason previously presented in the October 9, 2008 Response. Nevertheless, Applicants hereby cancelled claims 2-4 and 17-19 and amended claims 1 and 13 to positively recite "a creatine compound selected from the group consisting of creatine, creatine phosphate and cyclocreatine in an amount ranging from about 0.25 mM to about 1 mM," in order to expedite allowance of the present application. Applicants believe that the amended claims 1 and 13 of the present application are in full compliance with the enablement requirements of 35 U.S.C. §112, first paragraph.

Further, Applicants have cancelled previously withdrawn claims 20-24.

Correspondingly, all pending claims 1, 13, and 25-26 of the present application are in condition for allowance, and the Examiner is thereby requested to issue a Notice of Allowance in Applicants' favor.

Respectfully submitted,

Yongzhi Yang (Reg. No. 56,310) Estée Lauder Companies

155 Pinelawn Road, Ste. 345 S.

Melville, NY 11747

Telephone No.: 631-414-6089 Facsimile No.: 631-531-1340